MBX Biosciences, Inc. partners with HypoPARAassoc to advance treatment for over 100,000 hypoparathyroidism patients in U.S.

MBX Biosciences, Inc. partners with HypoPARAassoc to advance treatment for over 100,000 hypoparathyroidism patients in U.S.
MBX expands partnerships for hypoparathyroidism

MBX Biosciences, Inc. announced a partnership with HypoPARAassoc focused on accelerating progress for over 100,000 people in the U.S. affected by hypoparathyroidism, a rare endocrine disorder.

The company leverages its Precision Endocrine Peptide platform in an effort to advance therapies for patients with hypoparathyroidism. The collaboration underscores industry efforts to address unmet medical needs in the rare disease community.

MBX Biosciences previously presented new advances in precision peptide therapies at the Jefferies 2026 Global Healthcare Conference in New York. The company also released Phase 1 data for its GLP 1 GIP co-agonist candidate and outlined updates on its obesity treatment portfolio at Obesity Day. These activities highlight MBX’s ongoing focus on endocrine and metabolic disorder research.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.